Endocrinology, Vol 114, 629-637, Copyright © 1984 by Endocrine Society

ARTICLES

Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique

RL Eckert, A Mullick, EA Rorke and BS Katzenellenbogen

The level of estrogen receptor (ER) is a major factor regulating cell sensitivity to estrogen. We have determined the rates of ER synthesis and turnover in MCF-7 breast cancer cells by incubating cells in medium supplemented with 13C15N2H-amino acids (dense amino acids) and monitoring the shift from "old-light" (preexisting) to "new-dense" (newly synthesized) receptors by velocity sedimentation on 0.4-M KCl, 5- 20% sucrose gradients prepared in buffered deuterium oxide. Cytosol or unoccupied nuclear ER prepared from control cells grown in the presence of 12C14N1H-amino acids (normal amino acids) and labeled in vitro with [125I]iodoestradiol sediments as a single, normal density peak. When cells were incubated in medium supplemented with dense amino acids for various periods of time, the [125I]iodoestradiol-labeled receptor showed a progressive shift with time to a denser species; by 3 h, a more rapidly sedimenting shoulder was observed on the normal density peak; by 6 h, 40% of the receptor sedimented at the normal density rate, with 60% at a more rapid rate; by 8 h, the predominant peak (70%) was at the more dense position, and at 15 h, all of the sites sedimented as the denser form. Thus, the magnitude of the receptor peak of normal density as a function of time in dense medium indicates that the receptor in control cells has a half-life of 4.0-4.5 h. To determine whether estradiol or the antiestrogens nafoxidine (U11,100A; (1-(2-[p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy] ethyl)pyrrolidine hydrochloride) or CI628 affected the turnover rate of the receptor, measurements were performed on cells grown in the continuous presence of estradiol or antiestrogen (steady state conditions). Exposure of cells to 10 nM estradiol was found to increase the turnover rate of the nuclear receptor, while exposure to 200 nM nafoxidine or CI628 (alpha-(p-[2-(1-pyrrolidino)ethoxy]phenyl)4-methoxy- alpha'- nitrostillbene) did not substantially alter the turnover rate of the nuclear receptor. The half-lives of receptor were found to be 4.02 +/- 0.23 and 4.47 +/- 0.26 h for control unoccupied cytosol and nuclear receptors, 3.00 +/- 0.38 h for estradiol-occupied nuclear receptors, 4.90 +/- 0.66 h for CI628-occupied nuclear receptors, and 3.43 +/- 0.37 h for nafoxidine-occupied nuclear receptors. These results indicate that ER turns over rapidly, with a half-life of 3-5 h, in the presence or absence of estradiol or antiestrogen, and that receptor synthesis is also rapid, with the rate of appearance of newly synthesized receptor being 0.3-0.5 pmol/mg DNA . h. These rates provide the cell with the capacity for dynamic and rapid regulation of its ER levels.

This article has been cited by other articles:

				N. B. Berry, M. Fan, and K. P. Nephew Estrogen Receptor-{alpha} Hinge-Region Lysines 302 and 303 Regulate Receptor Degradation by the Proteasome Mol. Endocrinol., July 1, 2008; 22(7): 1535 - 1551. [Abstract] [Full Text] [PDF]

				C. C Valley, N. M Solodin, G. L Powers, S. J Ellison, and E. T Alarid Temporal variation in estrogen receptor-{alpha} protein turnover in the presence of estrogen J. Mol. Endocrinol., January 1, 2008; 40(1): 23 - 34. [Abstract] [Full Text] [PDF]

				E. T. Alarid Lives and Times of Nuclear Receptors Mol. Endocrinol., September 1, 2006; 20(9): 1972 - 1981. [Abstract] [Full Text] [PDF]

				W. R. Harrington, S. Sengupta, and B. S. Katzenellenbogen Estrogen Regulation of the Glucuronidation Enzyme UGT2B15 in Estrogen Receptor-Positive Breast Cancer Cells Endocrinology, August 1, 2006; 147(8): 3843 - 3850. [Abstract] [Full Text] [PDF]

				X. Long and K. P. Nephew Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate Immobilization and Degradation of Estrogen Receptor-{alpha} J. Biol. Chem., April 7, 2006; 281(14): 9607 - 9615. [Abstract] [Full Text] [PDF]

				M. Fan, A. Park, and K. P. Nephew CHIP (Carboxyl Terminus of Hsc70-Interacting Protein) Promotes Basal and Geldanamycin-Induced Degradation of Estrogen Receptor-{alpha} Mol. Endocrinol., December 1, 2005; 19(12): 2901 - 2914. [Abstract] [Full Text] [PDF]

				W. Shao, E. K. Keeton, D. P. McDonnell, and M. Brown Coactivator AIB1 links estrogen receptor transcriptional activity and stability PNAS, August 10, 2004; 101(32): 11599 - 11604. [Abstract] [Full Text] [PDF]

				H. Masuyama and Y. Hiramatsu Involvement of Suppressor for Gal 1 in the Ubiquitin/Proteasome-mediated Degradation of Estrogen Receptors J. Biol. Chem., March 26, 2004; 279(13): 12020 - 12026. [Abstract] [Full Text] [PDF]

				V. Marsaud, A. Gougelet, S. Maillard, and J.-M. Renoir Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor {alpha} (ER{alpha}), Differentially Affect ER{alpha} Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells Mol. Endocrinol., October 1, 2003; 17(10): 2013 - 2027. [Abstract] [Full Text] [PDF]

				M. Fan, R. M. Bigsby, and K. P. Nephew The NEDD8 Pathway Is Required for Proteasome-Mediated Degradation of Human Estrogen Receptor (ER)-{alpha} and Essential for the Antiproliferative Activity of ICI 182,780 in ER{alpha}-Positive Breast Cancer Cells Mol. Endocrinol., March 1, 2003; 17(3): 356 - 365. [Abstract] [Full Text] [PDF]

				A. S. Oh, L. A. Lorant, J. N. Holloway, D. L. Miller, F. G. Kern, and D. El-Ashry Hyperactivation of MAPK Induces Loss of ER{alpha} Expression in Breast Cancer Cells Mol. Endocrinol., August 1, 2001; 15(8): 1344 - 1359. [Abstract] [Full Text] [PDF]

				M. Maggiolini, O. Donze, E. Jeannin, S. Ando, and D. Picard Adrenal Androgens Stimulate the Proliferation of Breast Cancer Cells as Direct Activators of Estrogen Receptor {{alpha}} Cancer Res., October 1, 1999; 59(19): 4864 - 4869. [Abstract] [Full Text] [PDF]

				E. T. Alarid, N. Bakopoulos, and N. Solodin Proteasome-Mediated Proteolysis of Estrogen Receptor: A Novel Component in Autologous Down-Regulation Mol. Endocrinol., September 1, 1999; 13(9): 1522 - 1534. [Abstract] [Full Text]

				B. S. Katzenellenbogen and K. S. Korach Editorial: A New Actor in the Estrogen Receptor Drama--Enter ER-{beta} Endocrinology, March 1, 1997; 138(3): 861 - 862. [Full Text] [PDF]

				D. Macinga, V. Jain, N. Sizemore, G. I. Gorodeski, R. L. Eckert, and E. A. Rorke Tamoxifen Regulation of Ectocervical Cell Differentiation Reproductive Sciences, November 1, 1995; 2(6): 754 - 761. [Abstract] [PDF]

				A. L. Wijayaratne and D. P. McDonnell The Human Estrogen Receptor-alpha Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators J. Biol. Chem., September 14, 2001; 276(38): 35684 - 35692. [Abstract] [Full Text] [PDF]

				J.-M. Sun, H. Y. Chen, and J. R. Davie Effect of Estradiol on Histone Acetylation Dynamics in Human Breast Cancer Cells J. Biol. Chem., December 21, 2001; 276(52): 49435 - 49442. [Abstract] [Full Text] [PDF]